- HWI group
- Media centre
- Artificial Intelligence
Innovative Services for Pharma, Biotech & Medtech
The HWI group offers a broad range of individual and specialised pharmaceutical services for the pharma, biotech and medtech sector, particularly for active ingredients, medicinal products and medical devices. Benefit from our long-standing experience in laboratory services, vigilance and quality services, drug development as well as regulatory affairs services.
Company video
One click and a few minutes later, you’ll know who we are and what you can expect from us.
More videos are available at our media centre
AIQNET— Medical data ecosystem
HWI is part of a consortium that is one of the winners of the AI Innovation Competition by the Federal Ministry for Economic Affairs and Energy in 2019.
A digital ecosystem called AIQNET is being built collaboratively. The aim of the platform is to structure and use medical and clinical data in compliance with legal and ethical framework conditions. For more information – read here.
Services
Carieers
More than work
Working in the HWI group means joining a fantastic team, developing it, shaping it – and having fun!
News
Coronavirus measures of the HWI group
Until further notice, the HWI group will take the following measures to ensure that our services are maintained for you.
Click on "Read more" and read the measures in detail.
30 years HWI
30 years ago: On January 8th, 1991, the company was founded by Dr. Stefan Wissel and Prof. Dr. Hanns Häberlein. The two university friends created the name HWI from the first letters of their last names.
Expansion of the Management Team
As of January 1st, 2021, Dr Frank Böttcher will be appointed to the management team of HWI pharma services GmbH and will strengthen the current management team of Dr Stefan Wissel and Dr Melanie Kerst.
You will find further information in our press release.
Innovation and Technology Support
Innovative Screening and Technology Platform
The vast majority of new chemical and biological active pharmaceutical ingredients (API) are poorly soluble in water and physiological media. These active ingredients are difficult for the body to take up and are therefore poorly available at their target site in the body.
HWI plans to establish an innovative screening and technology platform for the fast, flexible and cost-effective development and manufacturing of parenteral (sterile) drug formulations with poorly soluble APIs. We therefore want to further develop nanotechnology for the improvement of bioavailability.
An application for funding for this project was submitted to the Innovation and Technology Support Programme (InnoTop) of the ISB Rhineland-Palatinate. This project will be supported by funding from the European Regional Development Fund (ERDF).
Contact us
Newsletter
Hotline